GE HealthCare has expanded its magnetic resonance imaging (MRI) contrast agent portfolio with the launch of Pixxoscan (gadobutrol).

Designed to enable the visualisation of abnormal structures or lesions, the new MRI agent helps differentiate between healthy and pathological tissue.

Pixxoscan is intended for contrast enhancement in cranial and spinal MRI as well as magnetic resonance angiography.

It is suitable for individuals across all age groups including adults, adolescents and children (including term neonates).

Pixxoscan is also recommended for whole-body imaging in individuals suspected to have focal lesions to determine whether they are benign or malignant.

GE HealthCare pharmaceutical diagnostics chief medical officer Mark Hibberd said: “This extension to our portfolio means we will be able to offer two leading macrocyclic molecules – Clariscan (gadoteric acid) and Pixxoscan (gadobutrol) – to our customers in a number of European countries, offering radiology departments even more choice to suit their diagnostic needs.”

Pixxoscan was assessed through a regulatory decentralised procedure (DCP) and already obtained marketing authorisation in Austria. DCP is a process to gain marketing authorisation in more than one European Union member state.

The company is currently awaiting approval for Pixxoscan and plans to introduce it in several European countries this year.

The company’s MRI contrast media portfolio also includes macrocyclic Clariscan (gadoteric acid) and Rapiscan.

Rapiscan is used in stress cardiac MR examinations to help diagnose coronary artery disease. For patients who are unable to exercise, it serves as a viable alternative used to simulate the same effect.